Clinical trials: Letrozole
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8
Hydroxychloroquine, Palbociclib, and Letrozole Before Surgery in Treating Patients With Estrogen Receptor Positive, HER2 Negative Breast Cancer
This phase I/II trial studies the side effects and best dose of hydroxychloroquine when given together with palbociclib and letrozole before surgery in treating patients with estrogen receptor positive, HER2 negative breast…
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
- Trial name
- NCT03774472
- Testing
- Hydroxychloroquine, Letrozole, Palbociclib
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- M.D. Anderson Cancer Center
Endometrial Cancer
RESOLVE: Abemaciclib + Letrozole +/- Metformin or Gedatolisib in Endometrial Cancer
This research study is studying a combination of targeted therapies as a possible treatment for estrogen-receptor positive (ER+) endometrial cancer.
- Trial name
- NCT03675893
- Testing
- Letrozole, Abemaciclib, LY3023414
- Where
- 3 sites in United States
- Volunteers
- 110 people
- Sponsor
- Dana-Farber Cancer Institute
Infertility
Letrozole Versus Laparoscopic Ovarian Drilling in Polycystic Ovary Syndrome
Polycystic ovary syndrome is the major cause of anovulatory infertility. Clomiphene citrate is the most commonly used oral agent for ovulation induction in this group, but there are some drawbacks with the use of it.
- Trial name
- NCT03009838
- Testing
- Letrozole, ovarian drilling
- Where
- Egypt
- Volunteers
- 150 people
- Sponsor
- Assiut University
Low-Grade Serous Ovarian Cancer
A Study of Avutometinib, Defactinib, and Letrozole in People With Low-Grade Serous Ovarian Cancer
The researchers are doing this study to find out whether the combination of avutometinib, defactinib, and letrozole is an effective treatment for people with low-grade serous ovarian cancer (LGSOC).
- Trial name
- CHAMELEON (NCT06394804)
- Testing
- Avutometinib, Defactinib, Letrozole
- Where
- 8 sites in United States
- Volunteers
- 20 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Breast Cancer
Letrozole in Preventing Breast Cancer in Postmenopausal Women Who Are at Increased Risk for Breast Cancer Due to High Breast Density
RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of letrozole may stop cancer from forming or coming back in postmenopausal women who are at increased risk for…
- Trial name
- NCT00238316
- Testing
- letrozole
- Where
- 10 sites in United States, Canada
- Volunteers
- 68 people
- Sponsor
- NCIC Clinical Trials Group
Breast Neoplasm
Everolimus and Letrozole as Preoperative Therapy of Primary Breast Cancer in Post-menopausal Women
The purpose of this study is to examine the effect of the combination of everolimus and letrozole compared to placebo and letrozole as pre-surgical therapy in patients with newly diagnosed estrogen receptor positive breast cancer.
- Trial name
- NCT00107016
- Testing
- RAD001, Letrozole 2.5mg, Letrozole 2.5mg
- Where
- 46 sites in United States, Austria and 8 more
- Volunteers
- 267 people
- Sponsor
- Novartis Pharmaceuticals
ER-Positive HER2-Negative Breast Cancer
Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)
The study is intended to show superiority of AZD9833 in combination with CDK4/6 inhibitor (palbociclib, abemaciclib or ribociclib) versus aromatase inhibitors (anastrozole or letrozole) in combination with CDK4/6 inhibitor in…
- Trial name
- SERENA-6 (NCT04964934)
- Testing
- AZD9833, Anastrozole, Letrozole
- Where
- 264 sites in United States, Australia and 21 more
- Volunteers
- 315 people
- Sponsor
- AstraZeneca
Medical Abortion, Complete or Unspecified, Without Complication
Randomized Study of Letrozole and Trilostane for Medical Abortion
In menstruation an effective shedding of the endometrial lining occurs. Both progesterone and estrogen levels fall sharply at this time.
- Trial name
- NCT01615211
- Testing
- Letrozole, Trilostane
- Where
- Sweden
- Volunteers
- 36 people
- Sponsor
- Kristina Gemzell Danielsson
Breast Cancer
Clinical Outcomes After Letrozole Treatment According to the Estrogen Receptor Expression in Postmenopausal Women
The purpose of this study is to assess clinical outcomes after Letrozole treatment according to the estrogen receptor expression in postmenopausal women with hormone receptor positive breast cancer.
- Trial name
- LETTER (NCT01069211)
- Where
- South Korea
- Volunteers
- 876 people
- Sponsor
- Korean Breast Cancer Study Group
Breast Cancer
Pyrotinib Maleate, CDK4/6 Inhibitor and Letrozole in Combination for Stage II-III TPBC: a Phase II Trial
The emergence of CDK4/6 inhibitors has brought hope to breast cancer patients resistant to endocrine therapy. In the mouse model, pyrotinib maleate combined with CDK4/6 inhibitor exhibits higher anti-tumor activity than any…
- Trial name
- NCT04486911
- Testing
- Pyrotinib maleate, SHR6390, letrozole
- Where
- China
- Volunteers
- 89 people
- Sponsor
- Shengjing Hospital
Breast Neoplasms
Study of Efficacy, Safety, and Pharmacokinetics of FCN-437c in Combination With Fulvestrant or Letrozole+Goserelin
This is a multicenter, open-label clinical study to evaluate the safety and antitumor activity of FCN-437c in combination with Fulvestrant for the treatment of post-menopausal female patients with ER+ and HER2- advanced breast…
- Trial name
- NCT05004142
- Testing
- FCN-437c+Fulvestrant, FCN-437c+Letrozole+Goserelin
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Ahon Pharmaceutical Co., Ltd.
Hormone-receptor-positive Breast Cancer, Early Breast Cancer
Clinical Study of Local and Systemic Biological Impact of GLP1/GIP-Receptor Agonists in Patients With Breast Cancer: The CLARA Trial
The CLARA trial is a phase II window-of-opportunity trial evaluating how a commonly used weight-loss medication (tirzepatide, a GLP-1/GIP receptor agonist) affects breast cancer biology, alone and in combination with standard…
- Trial name
- CLARA (NCT07676331)
- Testing
- Tirzepatide, Letrozole (Aromatase Inhibitors)
- Volunteers
- 168 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Breast Cancer
Letrozole Plus Ribociclib or Placebo as Neo-adjuvant Therapy in ER-positive, HER2-negative Early Breast Cancer
The purpose of this study is to determine if ribociclib in combination with letrozole for 24 weeks as neoadjuvant endocrine therapy increases the proportion of women with Pre-operative Endocrine Prognostic Index (PEPI) score of 0…
- Trial name
- FELINE (NCT02712723)
- Testing
- Letrozole, Ribociclib
- Where
- 13 sites in United States
- Volunteers
- 121 people
- Sponsor
- Qamar Khan
PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries
Comparison Between Two Ovulation Induction Therapies and LOD on Clinical Outcomes in CC-Resistant PCOS Women
Polycystic ovary syndrome (PCOS) is a prevalent endocrine disorder affecting 4-8% of reproductive-aged women and is a leading cause of infertility due to oligo-anovulation (1).
- Trial name
- NCT06486870
- Testing
- Gonadotropin, Letrozole, laparoscopic ovarian drilling
- Where
- Egypt
- Volunteers
- 183 people
- Sponsor
- Cairo University
Breast Cancer
Retrospective Analysis of Effectiveness and Safety Profile of Anastrozole and Letrozole in HR+ Breast Cancer Patients
This is a single centre, observational and retrospective clinical study. The study group was about all HR positive postmenopausal breast cancer patients who were hospitalized between January, 2008 and October, 2010, and ever…
- Trial name
- NCT02812277
- Volunteers
- 1,000 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Breast Cancer
Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer
The purpose of this study is to understand the safety and effects of the study medicine vepdegestrant (ARV-471/PF-07850327) given together with palbociclib in advanced breast cancer.
- Trial name
- VERITAC-3 (NCT05909397)
- Testing
- Vepdegestrant (ARV-471/PF-07850327), Palbociclib, Letrozole
- Where
- 29 sites in United States, Australia and 8 more
- Volunteers
- 59 people
- Sponsor
- Pfizer
Breast Cancer
Pyrotinib Combined With Dalpiciclib Combined With Letrozole in ER-positive and HER2-positive Advanced Breast Cancer
This is a a multicenter Phase II clinical study investigating efficacy of pyrotinib combined with dalpiciclib combined with letrozole in ER-positive and HER2-positive advanced breast cancer patients. The sample size is 63.
- Trial name
- NCT07014410
- Testing
- pyrotinib dalpiciclib letrozole
- Where
- China
- Volunteers
- 63 people
- Sponsor
- Zhejiang Cancer Hospital
Breast Cancer
Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS)
This research study is evaluating how well Breast Cancer responds to preoperative treatment with Endocrine treatment in combination with a drug called Palbociclib or Endocrine treatment alone as possible treatments for Hormone…
- Trial name
- NCT02764541
- Testing
- Letrozole, Tamoxifen, Palbociclib
- Where
- 11 sites in United States
- Volunteers
- 195 people
- Sponsor
- Dana-Farber Cancer Institute
Neoadjuvant Operable Breast Cancer
Efficacy of Letrozole + Palbociclib Combination as Neoadjuvant Treatment of Stage II-IIIA PAM 50 ROR-defined Low or Intermediate Risk Luminal Breast Cancer, in Postmenopausal Women
The investigators propose in the present study an innovative approach, combining the most recent therapeutic opportunities in high risk ER+ breast cancer with the most recent and innovative diagnostic approaches such as the PAM50…
- Trial name
- NeoPAL (NCT02400567)
- Testing
- Fluorouracile, Epirubicin, Cyclophosphamide
- Where
- 2 sites in France
- Volunteers
- 125 people
- Sponsor
- UNICANCER
Breast Cancer Female
Pre-Operative Window of Adjuvant Endocrine Therapy to Inform RT Decisions in Older Women With Early-Stage Breast Cancer
This is a prospective multisite exploratory study for women ≥ 65 years of age with early stage estrogen receptor positive (ER+) breast cancer.
- Trial name
- POWER (NCT04272801)
- Testing
- tamoxifen, letrozole, anastrozole, or exemestane, Patient reported outcomes
- Where
- 2 sites in United States
- Volunteers
- 84 people
- Sponsor
- Shayna Showalter, MD